Biotech IV Monitor

KNSA — Kiniksa Pharmaceuticals International plc

$4.8B market cap · 2 upcoming readouts tracked

Clinical trial readout dates for Kiniksa Pharmaceuticals International plc, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2027.

Next readoutDecember 2027in ~13 months
Upcoming readouts21 Phase 3
Market cap$4.8B
Cash & investments$576Mas of Sep 30, 2026
Recent 8-K filings1latest 2026-10-27

Upcoming readouts

Phase 2/3 KPL-387
Pericarditis; Pericarditis Acute · NCT07010159
December 2027
Recruiting
Phase 2 KPL-387
Recurrent Pericarditis; Heart Diseases · NCT07288216
December 2027
Recruiting

Cash position

Kiniksa Pharmaceuticals International plc reported $576M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-27). It reported net income of $47M for that quarter.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-10-27

Companies working on similar indications

Discussion

No messages yet. If you follow KNSA, you can start the conversation.
Track KNSA in real time
See live implied volatility for KNSA and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on KNSA
Contact — questions or corrections about KNSA: dukeupt@gmail.com